CALCA and migraine disorder: Yet, despite the clinical efficacy of anti-CGRP monoclonal antibodies in the prevention of migraines, the anti-CGRP monoclonal antibody, fremanezumab, has no dilatory or constrictive effects on these arteries and does not cause PPE [18].